The Long Run with Luke Timmerman

Ep210: Cameron Turtle on Long-Lasting Antibodies for Immune Disorders

Cameron Turtle, CEO of Waltham, Mass.-based Spyre Therapeutics, on developing long-lasting antibodies for immune disorders.

Ep209: Mathai Mammen on Developing Drugs Against Undruggable Targets

Mathai Mammen, CEO of Cambridge, Mass.-based Parabilis Medicine, on developing alpha helical peptide molecules against hard targets of disease.

Ep208: Gary Nabel on Developing a Vaccine for Epstein-Barr Virus

Gary Nabel, CEO of Weston, Mass.-based ModeX Therapeutics, on developing a vaccine for Epstein-Barr Virus.

Ep207: Jason Coloma on Genetic Medicines for Kidney Diseases

Jason Coloma, CEO of South San Francisco-based Maze Therapeutics, on developing small molecule drugs based on human genetics for kidney diseases.

Ep206: Lyn Baranowski on Inhalable Medicines for Severe Lung Diseases

Lyn Baranowski, CEO of Boston-based Avalyn Pharma, on developing inhalable medicines for severe lung diseases.

Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With

Heather Turner, CEO of New York-based LB Pharma, on developing a new schizophrenia drug designed to better cross the blood-brain barrier, be dosed once daily, and make it

Ep204: Troy Wilson on Precision Cancer Drugs and Combos

Troy Wilson, CEO of San Diego-based Kura Oncology, on his career in biotech and developing targeted cancer drugs.

Ep203: Sri Kosuri on Small Molecule Correctors of Disease

Sri Kosuri, co-founder and CEO of Emeryville, Calif.-based Octant Bio, on small molecules designed to correct protein misfolding and mistrafficking at the root of many di

Ep202: Becky Pferdehirt on Reimagining Science for the AI Era

Becky Pferdehirt, CEO of Emeryville, CA-based Radial, the life sciences unit of Astera Institute, on reimagining biology to take advantage of advances in AI.

Ep201: Jeremy Levin on Biotech in the Balance

Jeremy Levin, executive chair of Ovid Therapeutics, discusses his new book "Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust."

Ep200: Richard Pops Reflects on a 35-Year Career in Biotech

Alkermes CEO Richard Pops reflects on his 35-year career leading the company and its new opportunity in orexin biology for sleep disorders and more neurological condition

Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era

Marty Burke, a professor of chemistry at the University of Illinois and co-founder of Excelsior Sciences, on making small molecule synthesis more automated for AI.

Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery

Abbas Kazimi, CEO of Boston-based Nimbus Therapeutics, on computation and culture for drug discovery.

Ep197: Viswa Colluru on Discovering Drugs Inspired by Mother Nature

Viswa Colluru, founder and CEO of Boulder, Colo.-based Enveda, on drug discovery with a chemistry platform inspired by natural products.

Ep196: Otello Stampacchia on Europe's Biotech Crisis

Otello Stampacchia, founder and managing director of Omega Funds, on attempting to reform Europe's biotech investment climate.

Ep195: Ken Song on T-cell Engagers for Autoimmune Diseases

Ken Song, CEO of San Diego-based Candid Therapeutics, on developing bispecific T-cell engaging antibodies for autoimmune disease.

Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery

Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery by Timmerman Report

Ep193: Ron Renaud on Helping People Lose Weight With GLP-1 Medicines

Ron Renaud, CEO of Waltham, Mass.-based Kailera Therapeutics, on developing GLP-1 based medicines to help people lose weight and live healthier lives.

Ep192: Kate Haviland on Following the Science to Precision Immunology

Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.

Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease

Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).